Crinetics Pharmaceuticals (CRNX) Common Equity (2017 - 2026)

Crinetics Pharmaceuticals' Common Equity history runs 10 years deep, the most recent figure standing at $1.3 billion for Q1 2026.

• In Q1 2026, Common Equity rose 2.12% year-over-year to $1.3 billion; the TTM figure through Mar 2026 stood at $1.3 billion (up 2.12% YoY), while the FY2025 annual figure was $992.1 million, down 25.11% from the prior year.
• Common Equity was $1.3 billion for Q1 2026 at Crinetics Pharmaceuticals, up from $992.1 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $1.3 billion in Q4 2024 to a low of $254.1 million in Q2 2023.
• Historically, Common Equity has averaged $741.9 million across 5 years, with a median of $830.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Common Equity slumped 34.19% in 2023, then soared 226.92% in 2024.
• A 5-year view of Common Equity shows it stood at $316.3 million in 2022, then soared by 70.43% to $539.1 million in 2023, then surged by 145.74% to $1.3 billion in 2024, then retreated by 25.11% to $992.1 million in 2025, then gained by 29.09% to $1.3 billion in 2026.
• The last three Common Equity figures came in at $1.3 billion (Q1 2026), $992.1 million (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.